BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 26390038)

  • 1. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody.
    Xu Z; Gao J; Yao J; Yang T; Wang D; Dai C; Ding Y
    FEBS Open Bio; 2021 Mar; 11(3):813-825. PubMed ID: 33449453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
    Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    Sikic BI; Lakhani N; Patnaik A; Shah SA; Chandana SR; Rasco D; Colevas AD; O'Rourke T; Narayanan S; Papadopoulos K; Fisher GA; Villalobos V; Prohaska SS; Howard M; Beeram M; Chao MP; Agoram B; Chen JY; Huang J; Axt M; Liu J; Volkmer JP; Majeti R; Weissman IL; Takimoto CH; Supan D; Wakelee HA; Aoki R; Pegram MD; Padda SK
    J Clin Oncol; 2019 Apr; 37(12):946-953. PubMed ID: 30811285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
    Qu T; Zhong T; Pang X; Huang Z; Jin C; Wang ZM; Li B; Xia Y
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
    Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
    Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.
    Wang T; Wang SQ; Du YX; Sun DD; Liu C; Liu S; Sun YY; Wang HL; Zhang CS; Liu HL; Jin L; Chen XP
    J Transl Med; 2024 Mar; 22(1):220. PubMed ID: 38429732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
    Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
    Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
    Swoboda DM; Sallman DA
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
    Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
    Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 38.